We concluded that the final diagnosis was a BRAF wild-type stage IV - right hallux cutaneous malignant melanoma - pT4NxM1, with lymph node metastasis and a suspicion of lung metastasis. Additionally, the report could determine on the immunohistochemistry tests that the tumor had microsatellite stable status (MSS). Although it is not mandatory or determined routinely, the expression of PD-L1 was evaluated by immunohistochemistry and the patient-analyzed PD-L1 status suggested an overexpression of PD-L1 (PD-L1 tumor proportion score > 51%). The gene discussed is BRAF; the disease is melanoma.